HNSAN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
SERB Partnership Strengthens LiquidityThe SERB transaction provides substantial upfront funding and expands Hansa’s commercial partnership footprint across multiple regions. Pro forma liquidity should extend runway, support U.S. launch preparation, and reduce immediate financing pressure while the company advances its pipeline.
Strong Confirmatory Clinical EfficacyMeaningful improvements in kidney function and dialysis outcomes support imlifidase’s clinical utility in highly sensitized transplant patients. Positive confirmatory and PAES results also strengthen the case for broader regulatory acceptance and continued physician adoption.
Clear U.S. Launch And Regulatory PathwayA defined PDUFA date and active preparation across major transplant centers give the company a concrete route toward entering the U.S. market. The targeted population and estimated opportunity could materially expand the commercial platform beyond current European sales.
Bears Say
Revenue Decline And Persistent UnprofitabilityThe sharp TTM revenue decline and deeply negative profitability indicate that the commercial business has not yet reached sufficient scale to cover operating costs. Continued losses could constrain investment capacity and make future earnings dependent on successful product expansion.
Negative Equity And High DebtNegative equity combined with substantial debt weakens financial flexibility and leaves less balance-sheet capacity to absorb execution setbacks. If losses persist, leverage may increase refinancing and solvency pressure even after the SERB-related liquidity improvement.
Elevated Antibody-mediated Rejection RateThe higher observed AMR rate is a clinically important consideration that may require additional monitoring and management in practice. Even with no AMR-related graft losses reported, it could complicate physician adoption, regulatory discussions, or treatment protocols.
Hansa Biopharma AB News
HNSAN FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Currently, no data Available
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is $7.21B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 52 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -$4.539 earnings per share for the quarter, missing the consensus estimate of -$0.598 by -$3.941.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 12.04.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -$4.539 in its last earnings report, missing expectations of -$0.598. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in MX:HNSAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
HNSAN Stock 12 Month Forecast
Average Price Target
―Alligator Bioscience AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Cantargia AB
―